Enkastim (TKD activated natural killer cells) / Multimmune, Alphageneron - LARVOL DELTA

Alphageneron Announces Successful Completion of FDA Pre-IND Meeting of Proposed Phase II Clinical Trial for NK Cell Therapy with Advanced (stage III & Stage IV) NSCLC Patients (GlobeNewswire) - "Alphageneron Pharmaceuticals, Inc...announces the successful completion of a pre-IND...meeting with the U.S. Food and Drug Administration ('FDA') regarding a proposed multi-site Phase II Clinical Trial plan for its ENKASTIM™ autologous NK cell therapy for treating advanced (stage III and stage IV) non-small cell lung cancer ('NSCLC')...'Based upon our recent FDA interaction, we are working diligently to finalize the protocol design to initiate our first multi-site Phase II Clinical Trial to treat patients with advanced (stage III and IV) NSCLC in 2022..."

FDA event • New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology